SP-20203

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameSP-20203
Drug Alias NameSP20203
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSarfez Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSarfez Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeN/A
Related LinksN/A